Which combined oral contraceptive (CHC) should be prescribed for a woman with dysmenorrhea?

Combined Hormonal Contraceptive Selection for Dysmenorrhea

For dysmenorrhea, prescribe a combined oral contraceptive containing either estetrol 15 mg/drospirenone 3 mg (E4/DRSP) or a formulation with 17β-estradiol/estradiol valerate rather than ethinyl estradiol-containing pills, and consider continuous dosing (skipping the hormone-free interval) for faster symptom relief.

Evidence-Based Rationale

First-Line CHC Selection

The most recent high-quality evidence demonstrates that newer estrogen formulations outperform traditional ethinyl estradiol (EE)-based pills for dysmenorrhea. A 2025 comparative study showed that women using CHCs containing E2 or E4 had significantly greater improvement in pain scores than those using EE-containing pills at both 3 months (p ≤ 0.001) and 6 months (p ≤ 0.009) 1. Specifically, E4 15 mg/DRSP 3 mg demonstrated pain relief comparable to dienogest (a potent progestin used for endometriosis) 1.

The 2026 systematic review confirms E4/DRSP has high-certainty evidence for dysmenorrhea relief from placebo-controlled trials, with the added benefit of less pronounced hemostatic effects compared to EE-containing formulations 2.

Dosing Regimen: Continuous vs. Cyclic

Start with continuous dosing for the first 3 months, then reassess. The evidence shows:

• Continuous CHC use reduces pain more effectively than standard 21/7 cyclic regimens in the short term (SMD -0.73,95% CI -1.13 to -0.34) 3
• Pain improvement is superior at 1 month (mean difference -27.3, p<0.001) and 3 months (mean difference -17.8, p=0.03) with continuous dosing 4
• By 6 months, both regimens achieve similar pain control, but continuous use provides faster relief when women need it most 4

The 2024 CDC guidelines support managing breakthrough bleeding in continuous CHC users with a 3-4 day hormone-free interval if needed, but caution against doing this more than once monthly to maintain contraceptive efficacy 5.

Practical Algorithm

Step 1: Choose the estrogen component

• Prefer: E4 15 mg or 17β-estradiol 1.5 mg formulations
• Alternative: Ethinyl estradiol 20-30 μg if newer formulations unavailable

Step 2: Select dosing schedule

• Initial 3 months: Continuous (no hormone-free days)
• After 3 months: Continue continuous if tolerated, or switch to cyclic 21/7 if patient prefers scheduled bleeding

Step 3: Manage breakthrough bleeding

• Reassure that irregular bleeding is expected (risk 39-60% vs 18% with placebo) 3
• If bothersome: Allow one 3-4 day hormone-free interval per month maximum 5
• NSAIDs for 5-7 days can reduce bleeding without stopping CHC 5

Safety Considerations

All CHCs increase adverse events compared to placebo (RR 1.31,95% CI 1.20-1.43) 3, specifically:

• Irregular bleeding: Most common (RR 2.63) but typically improves over time 3
• Headaches: Probably increased (RR 1.51) 3
• Nausea: Probably increased (RR 1.64) 3

However, E4/DRSP formulations show less hepatic and hemostatic impact than EE-containing pills in mechanistic studies, though long-term thromboembolic safety data from real-world use is still needed 2.

Common Pitfalls to Avoid

1. Don't wait to assess efficacy: CHCs work quickly—expect improvement within 1 month, maximal benefit by 3-6 months 6, 4

2. Don't abandon continuous dosing prematurely: Breakthrough bleeding is common initially but doesn't indicate treatment failure. The 2024 CDC guidelines explicitly state not to recommend hormone-free intervals during the first 21 days of continuous use 5

3. Don't prescribe EE-containing pills as first-line when alternatives exist: The comparative data clearly favors E4 or E2 formulations for pain outcomes 1

4. Don't forget contraceptive counseling: While treating dysmenorrhea, these medications provide robust contraception (Pearl Index <1 for E4/DRSP) 2

When CHCs May Not Be Optimal

If dysmenorrhea persists despite 3-6 months of optimized CHC therapy, consider that the patient may have secondary dysmenorrhea from endometriosis or other pathology requiring further evaluation 1, 7. The 2024 CDC guidelines recommend clinical assessment for underlying conditions if bleeding patterns remain problematic 5.